logo

For the Inventor, By the Inventor

Bedford, MA, United States of America

Ocular Therapeutix, Inc.


USPTO Granted Patents = 20


Trademarks = 4

Forward Citations = 32

Loading Chart...
Loading Chart...

24 inventors (with patents filed for the assignee):

goldMedal Charles D Blizzard (12 out of 21 patents)

silverMedal Michael Goldstein (12 out of 12 patents)

bronzeMedal Peter K Jarrett (12 out of 30 patents)

4.  Rami El-Hayek (8 out of 17 patents)

5.  Arthur Driscoll (6 out of 17 patents)

6.  Andrew Vanslette (5 out of 5 patents)

7.  Mark Silverberg (4 out of 8 patents)

8.  Joseph Iacona (4 out of 4 patents)

9.  Erica Kahn (4 out of 4 patents)

10.  Noah Silverberg (4 out of 4 patents)

11.  Timothy S Jarrett (3 out of 8 patents)

12.  Ankita D Desai (3 out of 5 patents)

13.  Zachary Lattrell (3 out of 3 patents)

14.  Erik Wong (3 out of 3 patents)

15.  Eric Dickinson (1 out of 1 patent)


20 patents:

1. 12758490 - Hydrogel implants for lowering intraocular pressure (2026-10-13),
2. 12751859 - Intracanalicular depot inserter device (2026-10-06),
3. 12453724 - Ocular implant containing a tyrosine kinase inhibitor (2025-10-28),
4. 12357565 - Ocular implant containing a tyrosine kinase inhibitor (2025-07-15),
5. 12329853 - Compositions and methods for treating ocular diseases (2025-06-17),
6. 12310890 - Punctal plug and bioadhesives (2025-05-27),
7. 12226341 - Implant injector device (2025-02-18),
8. 12161753 - Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent (2024-12-10),
9. 12150896 - Punctal plug and bioadhesives (2024-11-26),
10. 12144889 - Methods of treating allergic conjunctivitis (2024-11-19),
11. 12109302 - Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine (2024-10-08),
12. 12023276 - Intracanalicular depot inserter device (2024-07-02),
13. 11779536 - Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine (2023-10-10),
14. 11622935 - Methods of treating ocular diseases using polyalkylene glycol intracameral implants with polyactide travoprost particles (2023-04-11),
15. 11559429 - Punctal plug and bioadhesives (2023-01-24),
Company Overview
Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts, specializing in the development of innovative therapies for eye diseases and conditions. The company focuses on creating sustained-release drug delivery systems, particularly for ocular applications, aiming to improve patient outcomes and enhance the treatment experience. With a commitment to advancing ocular health, Ocular Therapeutix leverages its proprietary technology to address unmet medical needs in the ophthalmic space.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

20 Patents

#37 in Bedford, MA

#985 in Massachusetts

#16,395 in US

#31,264 in the World

Bedford, MA (US)
Bedford, MA, United States of America

Ocular Therapeutix, Inc.

Forward Citations = 32

24 inventors:

goldMedal Charles D Blizzard (12 out of 21 patents)

silverMedal Michael Goldstein (12 out of 12 patents)

bronzeMedal Peter K Jarrett (12 out of 30 patents)

4.  Rami El-Hayek (8 out of 17 patents)

5.  Arthur Driscoll (6 out of 17 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ocular Therapeutix, Inc.. Retrieved from https://idiyas.com/company/ocular-therapeutix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…